Paragon Biomedical - Advancing Research. Improving Life. Globally.

FOR IMMEDIATE RELEASE

CONTACT:
Jared Byer
Paragon Biomedical, Inc.
9685 Research Drive
Irvine, CA 92618
Phone: +1 913 980 0028
www.paragonbiomedical.com

PARAGON BIOMEDICAL ANNOUNCES EXPANDED MEDICAL MONITORING AND SAFETY SERVICES

Irvine, CA – Wednesday, March 26, 2008

IRVINE, CALIFORNIA // March 27, 2008 - Paragon Biomedical, Inc., a global contract research organization (CRO) that manages Phase I-IV clinical trials, today announced the expansion of its medical monitoring and safety services.

In making the announcement, Mark Harvill, Paragon’s President and Chief Operating Officer, introduced the company’s new Medical Director, Liza DeAnnuntis, MD, as well as Sachidananda Moorthy, MD as medical lead for India, and Marcin Koziej, MD, as medical lead CEE/Poland.

“At Paragon, we understand every phase of our customers’ clinical development needs centers on patient safety,” Harvill said. “The expansion of our Medical Affairs team, including global medical monitoring and pharmacovigilence capabilities, underscores our commitment to our customer’s focus on safety and to exceeding quality standards.”

Paragon’s Medical Monitoring and Safety team will provide comprehensive Medical Monitoring, Pharmacovigilance, Safety Report Writing, and Medical Information services in support of Phase I-IV clinical trials on an international, round-the-clock basis.

Harvill said the expansion is a significant milestone for Paragon because it represents a continuation of the company’s strategic global expansion, as well as its continued growth.

“Paragon already delivers a comprehensive array of clinical development services to the pharmaceutical, biotech and medical device industries. These additional capabilities allow us to broaden the geographic breadth and depth of those services to Paragon’s customers in targeted regions worldwide,” he said.

ABOUT PARAGON BIOMEDICAL Founded in 1989, Paragon Biomedical, Inc. is a privately held, woman-owned contract research organization (CRO) specializing in the management of global Phase I-IV clinical trials in key therapeutic areas including cardiology, CNS, infectious diseases, and general medicine. Paragon delivers services through its US-based headquarters in Irvine, California and international offices in the UK, Poland and India. Paragon operates through a decentralized business model supporting a network of professionals with the tools and skills to manage global projects seamlessly. Paragon’s unique corporate culture has attracted the industry’s top project managers, clinical research associates and executives who share a strong commitment to excellence, and the vision to make a difference through the passionate pursuit of better healthcare.

For more information, visit www.parabio.com or contact Lisa VanStaaveren at 949.224.2800 or email lvanstaaveren@parabio.com

Download PDF version of this press release

###